Literature DB >> 33709318

The use of extracorporeal CO2 removal in acute respiratory failure.

Raphaël Giraud1,2,3, Carlo Banfi4,5,6,7, Benjamin Assouline8,6,7, Amandine De Charrière8,6,7, Maurizio Cecconi9,10, Karim Bendjelid8,6,7.   

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) exacerbation and protective mechanical ventilation of acute respiratory distress syndrome (ARDS) patients induce hypercapnic respiratory acidosis. MAIN TEXT: Extracorporeal carbon dioxide removal (ECCO2R) aims to eliminate blood CO2 to fight against the adverse effects of hypercapnia and related acidosis. Hypercapnia has deleterious extrapulmonary consequences, particularly for the brain. In addition, in the lung, hypercapnia leads to: lower pH, pulmonary vasoconstriction, increases in right ventricular afterload, acute cor pulmonale. Moreover, hypercapnic acidosis may further damage the lungs by increasing both nitric oxide production and inflammation and altering alveolar epithelial cells. During an exacerbation of COPD, relieving the native lungs of at least a portion of the CO2 could potentially reduce the patient's respiratory work, Instead of mechanically increasing alveolar ventilation with MV in an already hyperinflated lung to increase CO2 removal, the use of ECCO2R may allow a decrease in respiratory volume and respiratory rate, resulting in improvement of lung mechanic. Thus, the use of ECCO2R may prevent noninvasive ventilation failure and allow intubated patients to be weaned off mechanical ventilation. In ARDS patients, ECCO2R may be used to promote an ultraprotective ventilation in allowing to lower tidal volume, plateau (Pplat) and driving pressures, parameters that have identified as a major risk factors for mortality. However, although ECCO2R appears to be effective in improving gas exchange and possibly in reducing the rate of endotracheal intubation and allowing more protective ventilation, its use may have pulmonary and hemodynamic consequences and may be associated with complications.
CONCLUSION: In selected patients, ECCO2R may be a promising adjunctive therapeutic strategy for the management of patients with severe COPD exacerbation and for the establishment of protective or ultraprotective ventilation in patients with ARDS without prognosis-threatening hypoxemia.

Entities:  

Keywords:  ARDS; COPD; ECCO2R; Extracorporeal carbon dioxide removal; Hypercapnia; Respiratory acidosis

Year:  2021        PMID: 33709318      PMCID: PMC7951130          DOI: 10.1186/s13613-021-00824-6

Source DB:  PubMed          Journal:  Ann Intensive Care        ISSN: 2110-5820            Impact factor:   6.925


  61 in total

1.  Percutaneous venovenous CO2 removal with regional anticoagulation in an ovine model.

Authors:  Victor J Cardenas; Lucinda Miller; James E Lynch; Michael J Anderson; Joseph B Zwischenberger
Journal:  ASAIO J       Date:  2006 Jul-Aug       Impact factor: 2.872

Review 2.  Ventilator-induced lung injury.

Authors:  Arthur S Slutsky; V Marco Ranieri
Journal:  N Engl J Med       Date:  2013-11-28       Impact factor: 91.245

3.  Extracorporeal Co2 removal for chronic obstructive pulmonary disease: too risky or ready for a trial?.

Authors:  Francois Beloncle; Laurent Brochard
Journal:  Crit Care Med       Date:  2015-01       Impact factor: 7.598

4.  Venovenous extracorporeal CO2 removal for early extubation in COPD exacerbations requiring invasive mechanical ventilation.

Authors:  Roberto Roncon-Albuquerque; Gustavo Carona; Aida Neves; Fernando Miranda; Salomé Castelo-Branco; Teresa Oliveira; José Artur Paiva
Journal:  Intensive Care Med       Date:  2014-09-30       Impact factor: 17.440

Review 5.  Ventilator-induced lung injury: lessons from experimental studies.

Authors:  D Dreyfuss; G Saumon
Journal:  Am J Respir Crit Care Med       Date:  1998-01       Impact factor: 30.528

6.  A Retrospective Observational Case Series of Low-Flow Venovenous Extracorporeal Carbon Dioxide Removal Use in Patients with Respiratory Failure.

Authors:  Caroline E Moss; Eleanor J Galtrey; Luigi Camporota; Chris Meadows; Stuart Gillon; Nicholas Ioannou; Nicholas A Barrett
Journal:  ASAIO J       Date:  2016 Jul-Aug       Impact factor: 2.872

Review 7.  Extracorporeal gas exchange for acute respiratory failure in adult patients: a systematic review.

Authors:  Matthieu Schmidt; Carol Hodgson; Alain Combes
Journal:  Crit Care       Date:  2015-03-16       Impact factor: 9.097

8.  The use of extracorporeal carbon dioxide removal to avoid intubation in patients failing non-invasive ventilation--a cost analysis.

Authors:  Stephan Braune; Hilmar Burchardi; Markus Engel; Axel Nierhaus; Henning Ebelt; Maria Metschke; Simone Rosseau; Stefan Kluge
Journal:  BMC Anesthesiol       Date:  2015-11-04       Impact factor: 2.217

Review 9.  Extracorporeal carbon dioxide removal for patients with acute respiratory failure secondary to the acute respiratory distress syndrome: a systematic review.

Authors:  Marianne Fitzgerald; Jonathan Millar; Bronagh Blackwood; Andrew Davies; Stephen J Brett; Daniel F McAuley; James J McNamee
Journal:  Crit Care       Date:  2014-05-15       Impact factor: 9.097

View more
  4 in total

1.  A Case of the Use of Extracorporeal Carbon Dioxide Removal in a Patient With COVID-19 Acute Respiratory Distress Syndrome.

Authors:  Tarek R Firzli; Sunil Sathappan; Faisal Siddiqui
Journal:  Cureus       Date:  2022-05-01

2.  ERS International Congress 2021: highlights from the Respiratory Intensive Care Assembly.

Authors:  Aileen Kharat; Carla Ribeiro; Berrin Er; Christoph Fisser; Daniel López-Padilla; Foteini Chatzivasiloglou; Leo M A Heunks; Maxime Patout; Rebecca F D'Cruz
Journal:  ERJ Open Res       Date:  2022-05-23

3.  Extracorporeal CO2 reduction for COVID-19: hypercapnic respiratory failure post extracorporeal membrane oxygenation.

Authors:  John J Taxiera; Gaetano Cambria; Emily Mackay
Journal:  BMJ Case Rep       Date:  2022-02-25

4.  Acute kidney injury and renal replacement therapy: terminology standardization.

Authors:  Thiago Reis; Vinicius Sardão Colares; Eduardo Rocha; Mauricio Younes-Ibrahim; Emerson Quintino de Lima; Lucia da Conceição Andrade; Daniela Ponce; José H Rocco Suassuna; Luis Yu
Journal:  J Bras Nefrol       Date:  2022 Jul-Sep
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.